Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 7
Submit an article Journal homepage
343
Views
1
CrossRef citations to date
0
Altmetric
Commentaries on selected article in this issue

BCL2 inhibition in double hit lymphoma

Mary Ann AndersonDivision of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;Department of Clinical Haematology and Bone Marrow Transplant, The Royal Melbourne Hospital, Parkville, Australia;Departments of Medical Biology and Medicine, Faculty of Medicine, University of Melbourne, Parkville, AustraliaCorrespondence[email protected]
,
David C. S. HuangDivision of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;Departments of Medical Biology and Medicine, Faculty of Medicine, University of Melbourne, Parkville, Australia
&
Andrew W. RobertsDivision of Cancer and Haematology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia;Department of Clinical Haematology and Bone Marrow Transplant, The Royal Melbourne Hospital, Parkville, Australia;Departments of Medical Biology and Medicine, Faculty of Medicine, University of Melbourne, Parkville, Australia
Pages 1928-1929 | Published online: 21 Jan 2015

References

  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002;346:235–242.
  • Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol 2012;30:3439–3443.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
  • Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319–2331.
  • Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419–2430.
  • Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011;17: 7785–7795.
  • Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359: 554–556.
  • Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cell Mol Dis 2001;27:206–216.
  • Johnson-Farley N, Veliz J, Bhagavathi S, et al. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma 2015;56:2146–2152.
  • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–208.
  • Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014;51: 219–227.
  • Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677–681.
  • Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68: 3421–3428.
  • Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008;105:17961–17966.
  • Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121:2285–2288.
  • Davids MS, Seymour J, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-hodgkin lymphoma: responses observed in diffuse large B cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 2014; 32(5 Suppl.): Abstract 8522.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.